Evidence map›Paper›PMID 15078939›Full record

ArticleJournal of virology2004

Ex vivo and in vivo biological effects of a truncated form of the receptor tyrosine kinase stk when activated by interaction with the friend spleen focus-forming virus envelope glycoprotein or by point mutation.

Karen Rulli, Takashi Yugawa, Charlotte Hanson, Delores Thompson, Sandra Ruscetti, Kazuo Nishigaki

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Karen RulliBasic Research Laboratory, National Cancer Institute-Frederick, Frederick, Maryland 21702-1201, USA.
Takashi Yugawa
Charlotte Hanson
Delores Thompson
Sandra Ruscetti
Kazuo Nishigaki
Frederick National Laboratory for Cancer Research · USNational Cancer Institute · US

Funding

Molecular Basis for the Pathogenesis of Murine RetrovirusesZIABC005657 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RUSCETTI, SANDRA K · 2009 to 2013
$5.2M
MOLECULAR BASIS FOR THE PATHOGENESIS OF MURINE RETROVIRUSESZ01BC005657 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RUSCETTI, SANDRA K · 1996 to 2008
$2.7M
6 · The paper itself

Abstract

The erythroleukemia-inducing Friend spleen focus-forming virus (SFFV) encodes a unique envelope protein, gp55, which interacts with the erythropoietin (Epo) receptor complex, causing proliferation and differentiation of erythroid cells in the absence of Epo. Susceptibility to SFFV-induced erythroleukemia is conferred by the Fv-2 gene, which encodes a short form of the receptor tyrosine kinase Stk/Ron (sf-Stk) only in susceptible strains of mice. We recently demonstrated that sf-Stk becomes activated by forming a strong interaction with SFFV gp55. To examine the biological consequences of activated sf-Stk on erythroid cell growth, we prepared retroviral vectors which express sf-Stk, either in conjunction with gp55 or alone in a constitutively activated mutant form, and tested them for their ability to induce Epo-independent erythroid colonies ex vivo and disease in mice. Our data indicate that both gp55-activated sf-Stk and the constitutively activated mutant of sf-Stk induce erythroid cells from Fv-2-susceptible and Fv-2-resistant (sf-Stk null) mice to form Epo-independent colonies. Mutational analysis of sf-Stk indicated that a functional kinase domain and 8 of its 12 tyrosine residues are required for the induction of Epo-independent colonies. Further studies demonstrated that coexpression of SFFV gp55 with sf-Stk significantly extends the half-life of the kinase. When injected into Fv-2-resistant mice, neither the gp55-activated sf-Stk nor the constitutively activated mutant caused erythroleukemia. Surprisingly, both Fv-2-susceptible and -resistant mice injected with the gp55-sf-Stk vector developed clinical signs not previously associated with SFFV-induced disease. We conclude that sf-Stk, activated by either point mutation or interaction with SFFV gp55, is sufficient to induce Epo-independent erythroid colonies from both Fv-2-susceptible and -resistant mice but is unable to cause erythroleukemia in Fv-2-resistant mice.

Indexed as

Point MutationAnimalsCell LineErythroid CellsErythropoietinGenetic VectorsLeukemia, Erythroblastic, AcuteMiceMice, Inbred C57BLReceptor Protein-Tyrosine KinasesRetroviridae InfectionsSpleen Focus-Forming VirusesTumor Virus InfectionsViral Envelope ProteinsErythropoietinglycoprotein gp55, Friend spleen focus-forming virusReceptor Protein-Tyrosine KinasesRON proteinViral Envelope Proteins

Identifiers

PMID15078939
PMCPMC387688
OpenAlexW2010985738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.